Asia
GeoVax Labs, Inc., a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancer, together with BravoVax, a vaccine developer in Wuhan, China, today announced the signing of a Letter of Intent to jointly develop a vaccine against the new coronavirus.
Bionetix, ProQinase and MercachemSyncom announced they have signed a joint multiyear integrated drug-discovery project, starting from target identification up to clinical candidate selection on an undisclosed target aimed at acute myeloid leukemia.
Non-Sedative Orexin Receptor Antagonist Proven Effective for Both Sleep Onset and Sleep Maintenance With No Meaningful Differences Between Dayvigo and Placebo on Next-Day Postural Stability or Memory and Improvement of Daily Functioning
The Chinese government is turning to a drug developed by AbbVie for HIV patients as a potential treatment for the outbreak.
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look.
Eisai Co., Ltd. has obtained the approvals of supplementary new drug applications in Japan for its in-house developed antiepileptic drug Fycompa for an additional indication for monotherapy of partial-onset seizures and an additional indication for partial-onset seizures in pediatric patients aged 4 years and older, as well as a new fine granule formulation.
The drug, a checkpoint inhibitor, met the primary endpoint of improved progression-free survival at the planned interim analysis.
Coherus BioSciences, Inc. announced the Company has entered into a licensing agreement with Innovent Biologics, Co., Ltd.,, a leading biopharmaceutical company headquartered in China, to commercialize Innovent’s biosimilar candidate to Avastin® in the United States and Canada.
Over the past year, the company strived to transform itself into becoming a frontrunner in multiple areas, including cell and gene therapies.
PhoreMost and Otsuka Pharmaceutical Co. entered into a multi-project collaboration to seek out disease-relevant pathways that can be exploited for the development of gene therapies to treat different illnesses.
PRESS RELEASES